Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and Pathological Responses in Borderline Resectable or Unresectable Stage III NSCLC By Ogkologos - June 3, 2025 250 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a multicentre cohort study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Her Mother Died of Breast Cancer When She Was Five. 16... June 25, 2019 Capmatinib Shows Activity in Advanced NSCLC with a MET Exon 14... September 8, 2020 With Two FDA Approvals, Prostate Cancer Treatment Enters the PARP Era June 11, 2020 Efficacy of Dabrafenib Plus Trametinib in First-Line Treatment for Children and... October 11, 2023 Load more HOT NEWS Spotlight On: Exercise Physiologists in Cancer Care Regional Node Radiotherapy Significantly Reduced Breast Cancer Mortality and All-Cause Mortality... For Hairy Cell Leukemia, Drug Combination Leads to Long-Lasting Remissions 4 Tips from Oncology Dietitians for Healthier Eating During Cancer
